Interstitial pneumonitis: Difference between revisions
Jump to navigation
Jump to search
m (1 revision imported) |
(→Clinic) |
||
Line 1: | Line 1: | ||
=== Clinic === | === Clinic === | ||
* Also named Interstitial Lung Disease (ILD) or Diffuse Parenchymal Lung Disease (DPLD) | * Also named [[Interstitial Lung Disease]] (ILD) or Diffuse Parenchymal Lung Disease (DPLD) | ||
*It is a group of respiratory diseases affecting the interstitium (the tissue and space around the Alveoli) of the lungs. | *It is a group of respiratory diseases affecting the interstitium (the tissue and space around the Alveoli) of the lungs. | ||
* It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. | * It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. | ||
Line 18: | Line 18: | ||
* Cryptogenic organizing pneumonia (COP): also known by the older name bronchiolitis obliterans organizing pneumonia (BOOP) | * Cryptogenic organizing pneumonia (COP): also known by the older name bronchiolitis obliterans organizing pneumonia (BOOP) | ||
* Lymphoid interstitial pneumonia (LIP) | * Lymphoid interstitial pneumonia (LIP) | ||
==== Secondary ==== | ==== Secondary ==== | ||
* Connective tissue and Autoimmune diseases | * Connective tissue and Autoimmune diseases | ||
** Sarcoidosis | ** [[Sarcoidosis]] | ||
** Rheumatoid arthritis | ** [[Rheumatoid Arthritis|Rheumatoid arthritis]] | ||
** SLE | ** [[SLE, Systemic lupus erythematosus|SLE]] | ||
** Systemic sclerosis | ** [[Systemic Sclerosis|Systemic sclerosis]] | ||
** Polymyositis | ** [[Polymyositis]] | ||
** Dermatomyositis | ** [[Dermatomyositis]] | ||
** Antisynthetase syndrome | ** Antisynthetase syndrome | ||
Line 34: | Line 35: | ||
** Organic: [[Hypersensitivity pneumonitis]] (extrinisic allergic alveolitis) | ** Organic: [[Hypersensitivity pneumonitis]] (extrinisic allergic alveolitis) | ||
* Drug-induced | * Drug-induced /Cigarette smoking | ||
* Infection | * Infection | ||
Line 47: | Line 46: | ||
* Malignancy:Lymphangitic carcinomatosis | * Malignancy:Lymphangitic carcinomatosis | ||
== Remedies == | |||
{| class="wikitable" | |||
|+ | |||
! colspan="2" | | |||
=== [[Banerji protocols]] === | |||
|- | |||
|First line | |||
| | |||
* Kali-c C200 one dose every 2 days | |||
* Hep C6 + Chell 6X, i=one dose every 3 hours alternately | |||
* In acute Cough and Dyspnea Ip C30 one dose every 2 hours | |||
|- | |||
|Second line | |||
| | |||
* Lach C200 one dose every 2 days | |||
* Bry C30 + Acon C200 + Kali-i C6 one dose every 3 hours alternately | |||
|} |
Revision as of 01:25, 10 November 2023
Clinic
- Also named Interstitial Lung Disease (ILD) or Diffuse Parenchymal Lung Disease (DPLD)
- It is a group of respiratory diseases affecting the interstitium (the tissue and space around the Alveoli) of the lungs.
- It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues.
- It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.
Causes
Idiopathic
- Idiopathic pulmonary fibrosis (IPF): the most common subgroup
- Desquamative interstitial pneumonia (DIP)
- Acute interstitial pneumonia (AIP): also known as Hamman-Rich syndrome
- Nonspecific interstitial pneumonia (NSIP)
- Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)
- Cryptogenic organizing pneumonia (COP): also known by the older name bronchiolitis obliterans organizing pneumonia (BOOP)
- Lymphoid interstitial pneumonia (LIP)
Secondary
- Connective tissue and Autoimmune diseases
- Sarcoidosis
- Rheumatoid arthritis
- SLE
- Systemic sclerosis
- Polymyositis
- Dermatomyositis
- Antisynthetase syndrome
- Inhaled substances (Pneumoconiosis)
- Inorganic (Silicosis, Asbestosis, Berylliosis, Industrial printing chemicals)
- Organic: Hypersensitivity pneumonitis (extrinisic allergic alveolitis)
- Drug-induced /Cigarette smoking
- Infection
- COV-19
- Atypical pneumonia
- Pneumocystis pneumonia (PCP)
- Tuberculosis
- Chlamydia trachomatis
- RSV
- Malignancy:Lymphangitic carcinomatosis
Remedies
Banerji protocols | |
---|---|
First line |
|
Second line |
|